Centers for Disease Control and Prevention
Total Page：16
File Type：pdf, Size：1020Kb
CENTERS FOR DISEASE CONTROL AND PREVENTION NATIONAL IMMUNIZATION PROGRAM RECORD OF THE MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES June 23-24, 2004 Atlanta Marriott Century Center Hotel Atlanta, Georgia Table of Contents NEEDS FORMATTING TO ALIGN COLUMNS JUNE 23, 2004 ............................................................................................................................................1 Opening Comments .................................................................................................................................1 Hepatitis A Update................................................................................................................................2 Progress in Hepatitis A Prevention..................................................................................................2 Merck Presentation: Hepatitis A Vaccine (VAQTA® ...............................................................................4 GSK Presentation of Hepatitis A Vaccine................................................................................................5 Alaska Study of Interference With Maternal Antibody .............................................................................6 IOM Immunization Safety Review Report................................................................................................7 Public Comment......................................................................................................................................9 Influenza Program...................................................................................................................................9 Influenza-Associated Mortality/Encephalopathy in Children....................................................................9 Influenza Vaccine 2005-05 Supply Update ............................................................................................11 Kaiser Pediatric Vaccine Effectiveness Study, .......................................................................................12 Influenza Vaccine Effectiveness, University Student Population.............................................................14 Case-Control Influenza VE Study, Persons Aged 50-64 Years ................................................................15 Update: National Influenza Vaccine Summit ........................................................................................17 Priming and the Pediatric Influenza Immunization Dosing Schedule......................................................18 Update: Pandemic Influenza Preparedness and Response Plan ..............................................................20 Statement on Influenza Immunization of Health Care Workers ..............................................................22 Adult Immunization: NFID/National Coalition Presentation...................................................................25 Adult Immunization Schedule 2004-2005 ............................................................................................25 Vote ...............................................................................................................................................26 Pilot Project to Enhance Public Participation .........................................................................................26 Agency Updates.....................................................................................................................................29 Public Comment....................................................................................................................................31 JUNE 24, 2004 ..........................................................................................................................................31 Healthcare Worker Influenza Vaccination Recommendations....................................................................31 Vote ...............................................................................................................................................34 Meningococcal Disease: Meningococcal Workgroup Report....................................................................34 Cost Effectiveness of Meningococcal Vaccine Use in the U.S. ................................................................35 Scenarios of Meningococcal Vaccine Use .............................................................................................38 Public Comment....................................................................................................................................41 Smallpox: National Smallpox Vaccine in Pregnancy Registry Analysis....................................................41 Smallpox Workgroup Report................................................................................................................43 Influenza: Vaccine Efficacy of Partial Vaccination Schedules ...................................................................43 Prevnar Supply Status .........................................................................................................................44 High Risk Groups Who Should Receive Four Doses ..............................................................................44 Pertussis: Newer Macrolide Antibiotics in Treatment/Prophylaxis ..........................................................46 Combination Vaccine Recommendations................................................................................................47 Workgroup Updates ..............................................................................................................................48 Closing Comments.................................................................................................................................51 Public Comment....................................................................................................................................51 Certification ..........................................................................................................................................52 CENTERS FOR DISEASE CONTROL AND PREVENTION NATIONAL IMMUNIZATION PROGRAM ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES MINUTES OF THE MEETING June 23-24, 2004 JUNE 23, 2004 A meeting of the Advisory Committee on Immunization Practices (ACIP) was convened by the Centers for Disease Control and Prevention’s (CDC) National Immunization Program (NIP) at the Atlanta Marriott Century Center Hotel in Atlanta, Georgia, on June 23-24, 2004. Membership announcements included the rotation of three new members onto the committee and the reappointment of Chair Dr. Myron Levin for another year. Certificates of appreciation were provided to retiring members Dr. Jaime DeSeda and Dr. Richard Zimmerman. The meeting agenda (posted on CDC’s Website, http://www.cdc.gov/nip/) addressed influenza, meningococcal disease, immunization of health care workers, adult immunization, the enhancement of public participation in vaccine policy formation, smallpox vaccination, the vaccine supply, pertussis, and updates by the ACIP workgroups. The meeting was convened by ACIP Chairmen Dr. Myron Levin at 8:50 a.m. Those present are listed on the attached sheets (Attachment #1). Opening Comments Acting ACIP Executive Secretary Dr. Steven Hadler made several announcements: C New ACIP members at this meeting were Ms. Lisa Stinchfield, NP (replacing Dr. Celine Hanson). Dr. Jonathan Abramson’s term was extended for another three years. Dr. Tracey Lieu and Dr. Julie Morita will attend as of the October meeting. C New liaisons were Dr. Jonathan Temte (AAP), Dr. Romeo Rodriguez (National Immunization Council/Child Health Program, Mexico), Dr. Dennis Brooks (NMA) and Dr. Charles Helms (NVAC) C ACIP Workgroups to confer at this meeting were those to address influenza, HPV, evidence-based recommendations, pertussis, meningococcus, and MMR/VZV C The ACIP home page is www.cdc.gov/nip/acip; e-mail is at [email protected]. C ACIP Protocol: The quorum of ACIP members must be maintained to conduct committee business. The ACIP Charter allows the Executive Secretary to temporarily designate ex officio members as voting members in the absence of a quorum (eight appointed members) of members qualified to vote. If voting, they are asked to disclose any potential conflicts of interest. Meeting time is reserved for public comment at scheduled intervals, but may also occur during open discussion if a speaker is recognized by the Chair. ACIP members with potential conflicts of interest are asked to disclose all vaccine-related work and financial interests, and to refrain from any discussion or vote that is related to such matters. When needed, however, limited waivers of such conflicts of interest are granted, to enable members’ expertise to be provided in their service on the Committee. Waivers may be issued, for example, to members who also conduct clinical vaccine trials or serve on Data Monitoring Boards (DSMB). 1 The members and liaisons then introduced themselves (see Attachment #1). Those reporting potential conflicts of interest were Dr. Abramson (a one-time consultation for Merck in 2003), Dr. Poland (Merck and VaxGen), Dr. Treanor (Protein Sciences Corporation, Viscount, MedImmuune and VaxGen, and Dr. Levin (clinical trials for GlaxoSmithKline [GSK], Merck, and Merck’s DSMB). AGENDA ITEMS Hepatitis A Update Overview: Summary of progress of hepatitis A prevention in the United States: recommendations, epidemiology, incidence,